Document:

EX-10.13

 Exhibit 10.13 

CONFIDENTIAL TREATMENT REQUESTED 

THIRD AMENDMENT 
 TO

 LICENSE AGREEMENT 

THIS THIRD AMENDMENT TO LICENSE AGREEMENT (this “Third Amendment”), effective April 15, 2008, is by and among:

 Angiotech Pharmaceuticals (US), Inc., a corporation organized and existing under the laws of the State of Washington, with
principal offices at North Bend, WA (“Angiotech US”); 
 Angiodevice International GmbH, a corporation organized and
existing under the laws of Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (“Angiodevice”); and 

Histogenics Corporation, a corporation organized and existing under the laws of the State of Delaware (formerly under the laws of
Massachusetts), with principal offices at 830 Winter Street, 3rd Floor, Waltham, MA 02451 (formerly at 100 Hospital Road, Malden, MA 02148) (“Histogenics”). 

WITNESSETH 

WHEREAS, Angiotech Biomaterials Corp. (“Biomaterials”), Angiodevice and Histogenics entered into that certain License
Agreement, effective as of May 12, 2005, pursuant to which Biomaterials and Angiodevice licensed to Histogenics the right to use certain domestic and foreign patents, patent applications and know how relating to the manufacture and use of CT3
(the “Original License Agreement”): 
 WHEREAS, effective as of November 4, 2005, all of the assets of
Biomaterials were sold to Angiotech US and Biomaterials was wound up; 
 WHEREAS, in connection with such sale of assets,
Biomaterials assigned the Agreement to Angiotech US and Angiotech US assumed all rights and obligations of Biomaterials under the Original License Agreement as if it were the original party thereto: 

WHEREAS, Angiotech US, Angiodevice and Histogenics entered into that certain Amendment to License Agreement, dated as of
August 31, 2007 (the “First Amendment”): 
 WHEREAS, Angiotech US, Angiodevice and Histogenics entered into
that certain Second Amendment to License Agreement, dated as of January 1, 2008 (the “Second Amendment”), (the Original License Agreement, as amended by the First Amendment and the Second Amendment, shall be referred to herein
as the “Agreement”); and 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 WHEREAS, Angiotech US, Angiodevice and Histogenics have determined that it is in their
best interests to further amend certain provisions of the Agreement. 
 NOW, THEREFORE, in consideration of the mutual
promises and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby, acknowledged, Angiodevice, Angiotech US and Histogenics hereby agree as follows: 

 

	1.	Amendment. 

 (a) Section 1 of the Second Amendment is hereby deleted in its
entirety. 
 (b) Section 3.2(a)(ii) of the First Amendment is amended by deleting it in its entirety and replacing it with the
following: 
 At any time prior to the first to occur of, (A) ****, or (B) **** (the “Exclusivity Deadline”),
Histogenics may elect to convert this License to one of exclusivity within the Field by giving notice to Angiotech and paying one million dollars ($1,000,000) to Angiotech (the “Exclusivity Payment”). Such Exclusivity Payment shall be made
in accordance with the schedule set out below, unless and until Histogenics closes an equity financing with proceeds to Histogenics in an amount not less than ****, whereby the Exclusivity Payment shall become due and payable in full within fifteen
(15) days of such closing: 
  

			
	****	 	Payable by ****;
		
	****	 	Payable by ****;
		
	****	 	Payable by ****;
		
	****	 	Payable by ****.

  

	2.	Miscellaneous. 

 2.1 Entire Agreement: Confirmation of Agreement. Except as
specifically otherwise amended as set forth herein, the Agreement shall continue in full force and effect. 
 2.2 Counterparts. This
Third Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures of the parties hereto will have the same effect as
original signatures. In making proof of this Third Amendment, it shall not be necessary to produce or account for more than one such counterpart. 

[Signature Page Follows] 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 2 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 IN WITNESS WHEREOF, the parties have caused this Third Amendment to be executed and delivered
by the respective duly authorized officers as of the date set forth above. 
  

													
	ANGIOTECH PHARMACEUTICALS (US), INC.	 		 	ANGIODEVICE INTERNATIONAL GmbH
					
	By:	 	 /s/ Thomas Bailey
	 		 	By:	 	 /s/ Harald Beck

		 	Name:	 	 Thomas Bailey 
	 		 		 	Name:	 	 Harald Beck 

		 	Title:	 	 Chief Financial Officer
	 		 		 	Title:	 	 Director

		 	Date:	 	04/29/08	 		 		 	Date:	 	12 May 2008
						
		 		 		 		 	By:	 	 /s/ Jürg Dannecker

		 		 		 		 		 	Name:	 	 Jürg Dannecker

		 		 		 		 		 	Title:	 	 Director

		 		 		 	Date:	 	6 May 2008
					
	HISTOGENICS CORPORATION	 		 		 		 	
						
	By:	 	  
	 		 		 		 	
		 	Name:	 		 		 		 		 	
		 	Title:	 		 		 		 		 	
		 	Date:	 		 		 		 		 	

  
 - 3 -EX-10.14

 Exhibit 10.14 

CONFIDENTIAL TREATMENT REQUESTED 

FOURTH AMENDMENT 
 TO

 LICENSE AGREEMENT 

THIS FOURTH AMENDMENT TO LICENSE AGREEMENT (this “Fourth Amendment”), effective November 1, 2008, is by and
among: 
 Angiotech Pharmaceuticals (US), Inc., a corporation organized and existing under the laws of the State of Washington, with
principal offices at North Bend, WA (“Angiotech US”); 
 Angiodevice International GmbH, a corporation organized and
existing under the laws of Switzerland, with principal offices at Dammstrasse 19, Postfach, CH-6301 Zug, Switzerland (“Angiodevice”); and 

Histogenics Corporation, a corporation organized and existing under the laws of the State of Delaware (formerly under the laws of
Massachusetts), with principal offices at 830 Winter Street, 3rd Floor, Waltham, MA 02451 (formerly at 100 Hospital Road, Malden, MA 02148) (“Histogenics”). 

WITNESSETH 

WHEREAS, Angiotech Biomaterials Corp, (“Biomaterials”), Angiodevice and Histogenics entered into that certain License
Agreement, effective as of May 12, 2005, pursuant to which Biomaterials and Angiodevice licensed to Histogenics the right to use certain domestic and foreign patents, patent applications and know how relating to the manufacture and use of CT3
(the “Original License Agreement”), a copy of which is attached hereto; 
 WHEREAS, effective as of November 4,
2005, all of the assets of Biomaterials were sold to Angiotech US and Biomaterials was wound up; 
 WHEREAS, in connection
with such sale of assets, Biomaterials assigned the Original License Agreement to Angiotech US and Angiotech US assumed all rights and obligations of Biomaterials under the Original License Agreement as if it were the original party thereto;

 WHEREAS, Angiotech US, Angiodevice and Histogenics entered into that certain Amendment to License Agreement, dated as of
August 31, 2007 (the “First Amendment”), that certain Second Amendment to License Agreement, dated as of January 1, 2008 (the “Second Amendment”), and that certain Third Amendment to License Agreement,
dated as of April 15, 2008 (the “Third Amendment” and together with the First Amendment and the Second Amendment, the “Prior Amendments”), copies of each are attached hereto (the Original License Agreement, as
amended by the Prior Amendments, shall be referred to herein as the “Agreement”); 
 WHEREAS, pursuant to
Section 3.2(a)(ii) of the Agreement, Histogenics has elected to convert the License (as defined in the Agreement) to one of exclusivity and has made 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
two installment payments of the Exclusivity Payment (also as defined in the Agreement) of **** on or prior to **** and **** on or prior to ****; and 

WHEREAS, Angiotech US, Angiodevice and Histogenics have determined that it is in their best interests to amend certain provisions of
the Agreement. 
 NOW, THEREFORE, in consideration of the mutual promises and agreements set forth herein, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Angiodevice, Angiotech US and Histogenics hereby agree as follows: 

1. Amendment. Section 3.2(a)(ii) of the Agreement is hereby amended and restated in its entirety to state as follows: 

At any time prior to **** (the “Exclusivity Deadline”), Histogenics may elect to convert this License to one of exclusivity
within the Field by giving notice to Angiotech (such election, the “Conversion to Exclusivity”) and by paying Angiotech an aggregate of $1,045,000 (the “Exclusivity Payment”) in four (4) installments in
accordance with the following schedule: 
  

			
	****	 	Due and payable on ****;
		
	****	 	Due and payable on ****;
		
	****	 	Due and payable on ****; and
		
	****	 	Due and payable on ****.

 Notwithstanding anything to the contrary herein, including Section 3.6, any Exclusivity Payment, or
portion thereof, that is due and payable and remains unpaid and outstanding shall accrue interest, compounded quarterly, at a rate equal to **** per annum or at such lower maximum rate of interest allowed by applicable law. 

2. Miscellaneous. 
 2.1 Effects of
Amendment on Payment Due ****. For the avoidance of doubt, the payment of **** due by **** under Section 3.2(a)(ii) of the Agreement as it existed prior to this Fourth Amendment shall not be considered to have been overdue by virtue of this
Fourth Amendment being effective after such date. 
 2.2 Entire Agreement; Confirmation of Agreement. Except as specifically
otherwise amended as set forth herein, the Agreement shall continue in full force and effect. 
 2.3 Counterparts. This Fourth
Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures of the parties hereto will have the same effect as original
signatures. In making proof of this Fourth Amendment, it shall not be necessary to produce or account for more than one such counterpart. 

[Signature Page Follows] 

  
 ****CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 

- 2 - 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 IN WITNESS WHEREOF, the parties have caused this Fourth Amendment to be executed and
delivered by the respective duly authorized officers as of the date set forth above. 
  

													
	ANGIOTECH PHARMACEUTICALS (US), INC.	 		 	ANGIODEVICE INTERNATIONAL GmbH
					
	By:	 	 /s/ David D. McMasters
	 		 	By:	 	 /s/ David D. McMasters

		 	Name:	 	 David D. McMasters 
	 		 		 	Name:	 	 David D. McMasters 

		 	Title:	 	 Sr. VP, Legal & General Counsel
	 		 		 	Title:	 	 Managing Director

		 	Date:	 	November 4, 2008	 		 		 	Date:	 	November 4, 2008
					
	HISTOGENICS CORPORATION	 		 		 		 	
						
	By:	 	 /s/ F. Ken Andrews
	 		 		 		 	
		 	Name:	 	F. Ken Andrews	 		 		 		 	
		 	Title:	 	CEO & President	 		 		 		 	
		 	Date:	 	11-5-08	 		 		 		 	

  
 - 3 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]